Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
- Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
- Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
June 22, 2021
- Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
June 1, 2021
- Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
February 9, 2021
- Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
- Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
December 28, 2020
- Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
October 23, 2020
- IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
September 16, 2020
- Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
September 9, 2020
- COVID-19 Pandemic to Test True Value of MHLW’s Officers with Medical/Pharma Backgrounds
August 26, 2020
- COVID-19’s Impact on Pharma Becoming Clearer with New Data, Earnings
August 17, 2020
- With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
- Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
July 22, 2020
- Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
- Will Zolgensma Delay Spur Revision of Sakigake Designation System?
June 11, 2020
- Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
May 7, 2020
- Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
- Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
- Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…